Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line

VERNON, BC, Jan. 6, 2022 /CNW/ – Doseology Sciences Inc. (CSE:MOOD) (“Doseology” or the “Firm”), a British Columbia-based diversified life sciences firm growing mushroom-based well being and wellness options, broadcasts the profitable smooth launch of seven new adaptogenic mushroom merchandise in america, and the upcoming launch of the product line within the Canadian market throughout the first quarter of 2022.

Doseology’s new medicinal mushroom merchandise have efficiently accomplished check advertising with overwhelmingly constructive scores and evaluations. Being among the many most complete obtainable in the marketplace, they are going to assist fill the rising demand for high-quality adaptogenic nutraceuticals. The brand new line employs adaptogenic blends to enhance on the single-extract tinctures generally obtainable. Blends have a better market worth due to elevated person advantages and growth challenges.

The proprietary formulations make in depth use of pure mushroom fruiting our bodies, pairing adaptogenic botanicals with nutritional vitamins for elevated efficacy. Important analysis has proven constructive results of adaptogens with respect to emphasize discount, resistance to psychological fatigue, and improved consideration capability. The Doseology line combines adaptogens resembling ginger, turmeric, yerba mate, and a number of other mushroom species, with confirmed purposeful mushrooms resembling lion’s mane, reishi, shiitake, maitake, royal solar, turkey tail, and others. These blended formulations ship enhanced well being and wellness advantages over single-ingredient merchandise.

The brand new product line addresses the purposeful mushroom market, projected to develop to US$572 billion globally by 2028 with a CAGR of 6.1 p.c (Information Bridge Market Analysis). Merchandise within the new Doseology line handle totally different segments of the market, together with temper and melancholy, consideration and focus, sleep and restoration, and anxiousness.

In preparation for the Canadian launch, Doseology has obtained six Pure Product Quantity (NPN) licenses from Well being Canada. The Firm is at present exploring Canadian distribution channels, which is deliberate to incorporate Amazon.ca. With US$7.14 billion in web gross sales (Statista, 2020), Amazon.ca is by a large margin Canada’s largest on-line retailer. The Firm’s direct advertising focus will allow it to shortly attain customers who can profit most, present an enticing buyer expertise, and set up long-term relationships to maximise income.

Daniel Vice, Doseology CEO and Director, feedback, “After many months of product growth, testing, and regulatory approval, we’re happy to lastly launch our merchandise within the U.S. market, and shortly in Canada. By incorporating the nutrient-dense fruiting our bodies of purposeful mushrooms and pure health-promoting adaptogens, our merchandise have been designed to optimize the person expertise which displays our dedication to ship high-quality, pure options to enhance bodily & psychological well being.”

A core factor of the Firm’s mission is growing and offering psychedelic therapies for restoring psychological well being. As soon as the regulatory framework has been established, Doseology’s product line will kind the muse for psilocybin-based therapeutics, creating a completely new market and fulfilling the Firm’s imaginative and prescient of higher psychological well being and wellness for tens of millions globally.

Doseology has accomplished its utility with Well being Canada to grow to be a “Licensed Seller” below the Managed Medicine and Substances Act (Canada), which might allow the manufacturing of psychedelic compounds together with psilocybin and psilocin, and mark a major milestone in reaching the Firm’s imaginative and prescient.

These introduced developments will give customers higher entry to the therapeutic energy of medicinal mushrooms, and convey Doseology nearer to delivering progressive wellness options and psychological well being therapies.

Be taught extra about Doseology’s medicinal mushroom product line at doseology.com.

On Behalf of the Board of Administrators

Daniel Vice
Chief Government Officer and Director
Doseology Sciences Inc.

About Doseology Sciences Inc.

Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based diversified life sciences firm, on a mission to reimagine psychological well being therapies via innovation, expertise and sustainability. With a concentrate on psychedelic and non-psychedelic compounds, Doseology will supply cutting-edge therapeutic services, with the purpose of constructing a significant affect on the psychological well being pandemic and enhancing total well being.

Ahead Wanting Statements

This company replace incorporates statements which represent “ahead–wanting info” throughout the that means of relevant securities legal guidelines. Ahead–wanting info is commonly recognized by the phrases “could,” “would,” “may,” “ought to,” “will,” “intend,” “plan,” “anticipate,” “imagine,” “estimate,” “count on” or related expressions. Readers are cautioned that ahead–wanting info is just not primarily based on historic info however as a substitute displays the Firm’s administration’s expectations, estimates or projections in regards to the enterprise of the Firm’s future outcomes or occasions primarily based on the opinions, assumptions and estimates of administration thought-about cheap on the date the statements are made. Though the Firm believes that the expectations mirrored in such ahead–wanting info are cheap, such info entails dangers and uncertainties, and undue reliance shouldn’t be positioned on such info, as unknown or unpredictable elements may have materials hostile results on future outcomes, efficiency or achievements. Among the many key elements that would trigger precise outcomes to vary materially from these projected within the ahead–wanting info are the next: adjustments typically financial, enterprise and political circumstances, together with adjustments within the monetary markets; decreases within the prevailing costs for merchandise within the markets that the Firm operates in; hostile adjustments in relevant legal guidelines or hostile adjustments within the utility or enforcement of present legal guidelines; rules and enforcement priorities of governmental authorities; compliance with authorities regulation and associated prices; and different dangers described within the Prospectus. Ought to a number of of those dangers or uncertainties materialize, or ought to assumptions underlying the ahead–wanting info show incorrect, precise outcomes could range materially from these described herein as meant, deliberate, anticipated, believed, estimated, or anticipated. Though the Firm has tried to determine essential dangers, uncertainties and elements which may trigger precise outcomes to vary materially, there could also be others that trigger outcomes to not be as anticipated, estimated or meant. The Firm doesn’t intend, and doesn’t assume any obligation, to replace this ahead–wanting info besides as in any other case required by relevant legislation.

No securities regulatory authority has both authorized or disapproved of the contents of this information launch. The Firm’s securities haven’t been, nor will they be, registered below america Securities Act of 1933, as amended, or any state securities legal guidelines, and is probably not supplied or offered in america, or to or for the account or advantage of any individual in america, absent registration or an relevant exemption from the registration necessities. This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase any securities in america, or in some other jurisdiction through which such supply, solicitation or sale can be illegal.

The CSE doesn’t settle for accountability for the adequacy or accuracy of this launch.